Fierce Pharma

JUNE 29, 2023

By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |

Sales 264

Sales 264

Fierce Pharma

NOVEMBER 14, 2023

Failure of the Imfinzi-concurrent-chemoradiotherapy regimen deals a blow to AZ’s goal to target more than half of lung cancer patients by 2030. . | One study in AstraZeneca’s elaborate R&D plan for lung cancer has reached a dead end.

Patients 246

Patients 246

Fierce Pharma

FEBRUARY 9, 2023

Now, it plans 15 drug launches by 2030 aliu Thu, 02/09/2023 - 10:00 AstraZeneca met CEO Pascal Soriot's $40B revenue goal early.

246

246

Fierce Pharma

NOVEMBER 1, 2024

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | So far, argenx's Vyvgart has reached 300 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after securing an FDA approval in (..)

FDA 310

FDA Patients 310

Fierce Pharma

OCTOBER 16, 2024

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030. |

290

290

pharmaphorum

MARCH 1, 2024

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.

133

133

Fierce Pharma

OCTOBER 2, 2023

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

Leads 173

Leads Sales Pharma 173

Fierce Pharma

JUNE 12, 2023

Bayer recently laid out its ambition | Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.

Sales goal 354

Sales goal Sales 354

Fierce Pharma

JUNE 13, 2024

Pfizer's oncology division plans to have eight blockbusters by 2030, with contributions from each of its four focused therapeutic areas.

290

290

Fierce Pharma

OCTOBER 31, 2024

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.

Sales goal 312

Sales goal Sales 312

pharmaphorum

MAY 21, 2024

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

119

119

Fierce Pharma

JUNE 17, 2024

As part of Vision 2030, argenx will touch on its continuing commitment to tackle severe autoimmune diseases with Vyvgart. As argenx homes in on the next indication for its pipeline-in-a-product Vyvgart (efgartigimod), the company is preparing for the next leg of its commercial journey. |

130

130

Fierce Pharma

JUNE 7, 2024

With 25 launches planned through 2030, Boehringer Ingelheim is gearing up for a busy few years. | The launches are part of the company's wider plan to bring 25 new products to the market by 2030.

Marketing 244

Marketing 244

Fierce Pharma

FEBRUARY 7, 2024

Overall, the company is pushing to generate 30% of its revenues from oncology by 2030. In 2023, the number was 11%.

296

296

Fierce Pharma

NOVEMBER 12, 2024

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper collection of patient data that have implicated senior executives, AstraZeneca CE | Despite China’s investigations that have implicated senior executives, AstraZeneca CEO Pascal Soriot argued that the company did not lose oversight and (..)

Insurance 321

Insurance Patients 321

MedCity News

FEBRUARY 17, 2023

For example, one said that healthcare will be close to establishing a value-based formulary by 2030, and another said that longitudinal patient tracking will become a more important part the drug pricing process. Panelists at a recent pharmacy conference were optimistic about the future of value-based drug contracting.

Healthcare 119

Healthcare Healthcare Patients Pharma 119

European Pharmaceutical Review

MARCH 28, 2024

billion by 2030. percent between 2024-2030. by 2030 appeared first on European Pharmaceutical Review. The global pharmaceutical and biotechnology environmental monitoring market valued $24 billion in 2023, according to a report by Verified Market Research. This figure is projected to increase to $38.1 PerkinElmer, Inc.

Pharmaceutical 98

Pharmaceutical Marketing Pharma Management 98

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Manufacturing 105

Manufacturing Pharma Pharmaceutical Marketing 105

European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. percent between 2023 and 2030. percent from 2023 to 2030. The post HPLC market projected to value $8 million by 2030 appeared first on European Pharmaceutical Review. What is driving the HPLC market?

Marketing 98

Marketing Biopharma Pharmaceutical Pharma 98

European Pharmaceutical Review

JULY 18, 2023

billion by 2030. Digitalisation to boost quality management systems market The post QMS market to value nearly $4b by 2030 appeared first on European Pharmaceutical Review. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Marketing 98

Marketing Management Manufacturing Pharmaceutical manufacturing 98

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Sales 98

Sales Pharma Government Medicine 98

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. billion by 2030 appeared first on European Pharmaceutical Review. According to a market report , the global RNA therapy clinical trials market is anticipated to reach $3.5

Marketing 98

Marketing Safety Pharmaceutical Medicine 98

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Marketing 96

Marketing Pharmaceutical Manufacturing Pharma 96

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Manufacturing 98

Manufacturing Marketing Side effects Transportation 98

Pharmaceutical Technology

DECEMBER 10, 2024

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Australia - is forecast to grow from $582m in 2020 to $6.2bn in 2030 at a compound annual growth rate of 26.7%, with the paediatric and adult segments (..)

Marketing 59

Marketing 59

Fierce Pharma

NOVEMBER 26, 2024

| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of zero dengue deaths by 2030.

Management 130

Management 130

pharmaphorum

DECEMBER 7, 2023

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

Sales 103

Sales 103

pharmaphorum

APRIL 16, 2024

Boehringer Ingelheim says the strongest R&D pipeline in its history is set to deliver 25 new product launches between now and 2030

116

116

European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Sartorius AG and Merck KGaA, Single-use technology propelling upstream bioprocessing market expansion The post Single-use bioreactor market to witness favourable expansion to 2030 appeared first on European Pharmaceutical Review.

Marketing 52

Marketing Manufacturing Medicine Leads 52

MedCity News

SEPTEMBER 6, 2024

By 2030, the U.S. expects shortages of 200,000 nurses and 124,000 physicians snd similar shortages are already being felt in the U.K. and elsewhere. Here’s how to build and train a modern healthcare workforce in the age of AI The post Can AI Help Fix Our Demographic Time Bomb? appeared first on MedCity News.

Physicians 122

Physicians Training Healthcare Healthcare 122

Pharmaceutical Commerce

APRIL 17, 2024

A panel uncovers the value in meeting carbon-neutral goals by 2030.

105

105

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review. The global buccal drug delivery market is projected to grow from $3.38

Marketing 52

Marketing Management Patients Pharmaceutical 52

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

Fierce Pharma

AUGUST 4, 2023

The company is sticking to its ambitions of pulling a third of its revenue from its oncology portfolio by 2030. For years, Gilead has been on a mission to become a power player in oncology. | This year, the company expects $3 billion to come from its cancer trio of Trodelvy, Tecartus and Yescarta.

130

130

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. With the personalised medicine market reaching $93bn by 2030, there will be a range of treatments available. It is the year 2030. If a vaccine is not yet available, and the cancer has begun to grow, personalised medicine will be your best therapeutic solution.

Healthcare 137

Healthcare Healthcare Electronics Healthcare Provider 137

Pharmaceutical Technology

SEPTEMBER 18, 2024

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.

Sales 98

Sales Patients FDA 98

PharmaVoice

FEBRUARY 20, 2024

By 2030, the AI market is expected to reach $187.95 A significant growth is predicted for both AI and IoT in healthcare. billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

Marketing 104

Marketing Healthcare Healthcare 104